

THROMBOPROPHYLAXIS FOR MEDICAL INPATIENTS

Date of admission: _____

Date of assessment: _____

Name: _____

Date of Birth: _____

Hospital No: _____ *Patient details or sticker*

NHS No: _____


Consultant: _____

MUST BE ASSESSED WITHIN 24 HOURS OF ADMISSION

Assessment by _____ (print name) Signature _____

Enoxaparin indicated? Yes No If yes and not given, please indicate why _____

Patients should have their VTE risk assessed should there be a change in their clinical condition



RISK FACTORS FOR VENOUS THROMBOEMBOLISM (VTE)

- | | |
|--|---|
| <input type="checkbox"/> Personal or family history VTE | <input type="checkbox"/> Heart or respiratory failure |
| <input type="checkbox"/> Acquired or inherited thrombophilia (incl. antiphospholipid syndrome) | <input type="checkbox"/> Myeloproliferative disease/ paroxysmal nocturnal haemoglobinuria |
| <input type="checkbox"/> Age older than 75 years | <input type="checkbox"/> Paraproteinaemia |
| <input type="checkbox"/> Obesity | <input type="checkbox"/> Inflammatory bowel disease |
| <input type="checkbox"/> Acute infection | <input type="checkbox"/> Nephrotic syndrome |
| <input type="checkbox"/> Inflammatory illness or Behcet's disease | <input type="checkbox"/> Paralysis/ paresis/ limb in plaster |
| <input type="checkbox"/> Cancer or cancer therapies | <input type="checkbox"/> Hormone therapy (antiandrogen or oestrogen) |

THROMBOPROPHYLAXIS FOR MEDICAL INPATIENTS

Additional Information

ALL PATIENTS:

- Encourage early mobilisation and leg exercises
- Ensure adequate hydration
- Assess patient's risk factors for VTE on admission and prescribe thromboprophylaxis as indicated (see chart overleaf).
- **Patients should be have their VTE risk reassessed should there be a change in their clinical condition**
- All stroke patients admitted to hospital should be assessed for graduated elastic compression stockings (GECS) and for inclusion into multi-centred trial (CLOTs)

Prescription:

- Enoxaparin should be prescribed on the patients drug chart and given once a day at 18.00.
- If heparin exposure within 3 months check full blood count (FBC) next day.
- FBC should be checked after 5-7 days then again after 12-14 days of therapy to exclude heparin induced thrombocytopenia (contact haematology if platelet count falls by 30-50% or less than $150 \times 10^9 / L$).

Contraindications to chemical thromboprophylaxis:

- Known bleeding disorder/thrombocytopenia (platelet count less than $50 \times 10^9/L$)
- On therapeutic anticoagulation (oral anticoagulants / un-fractionated heparin / enoxaparin / fondaparinux)
- Recent haemorrhagic stroke or risk of central nervous system bleed e.g. head injury (caution in recent ischaemic stroke, see separate guidance)
- Active gastrointestinal bleeding
- Bacterial endocarditis, pericarditis or thoracic aortic aneurysm (discuss with cardiologist)
- Heparin induced thrombocytopenia or hypersensitivity to enoxaparin
- Severe hepatic failure

OR

- Other conditions with high risk of serious bleed
- **Discuss with Consultant if risk/benefit balance not clear**

If thromboprophylaxis is contraindicated consider using GECS

NB

- Enoxaparin is licensed for prophylactic use in medical patients for a minimum of 6 and a maximum of 14 days. Continuation for more than 14 days should be undertaken after assessment of the risk: benefit of prolonged treatment.

Calculation for creatinine clearance (Cockcroft-Gault Equation)

$$\left(\frac{(140 - \text{age}) \times \text{weight (kg)}}{\text{Serum Creatinine (micromol/L)}} \right) \times \begin{matrix} 1.04 \text{ (female)} \\ \text{or} \\ 1.23 \text{ (male)} \end{matrix} = \text{CrCl (ml/min)}$$